AFFX Affymetrix, Inc.

Perlegen Sciences Appoints Robert Middlebrook to Head Corporate Development MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire/ -- Perlegen Sciences, Inc., a privately held genetics company, today announced that Robert Middlebrook has joined Perlegen in the newly created role of Chief Corporate Development Officer. "Perlegen is expanding its roster of world class corporate, government and academic partners and simultaneously moving rapidly toward the in-licensing of late-stage drug candidates," said Brad Margus, Chief Executive Officer of Perlegen. "As a general manager, Rob has helped lead a number of organizations through significant change, while as an investment professional, he has managed billions of dollars of institutional capital. With this rare blend of skills, Rob will help Perlegen accelerate its migration from development to production in specific therapeutic areas by positioning us most effectively in the capital markets and in the competitive markets within which we operate." Mr. Middlebrook joins Perlegen following an eleven year tenure with Fidelity Investments where he held a number of key leadership positions in the firm's money management operation, including Chief Investment Officer of the Managed Income Group and Head Trader of the Municipal Money Market Group. More recently, in the role of Senior Vice President, Mr. Middlebrook lead reengineering efforts in the firm's supply management operation, overseeing the company's multi-billion annual spend on goods and services, and in Fidelity's HR and payroll outsourcing practice. Prior to joining Fidelity, Mr. Middlebrook was Vice President and Principal of Regent Capital Corporation where he was responsible for structuring a broad range of investment opportunities and corporate development transactions. He also spent four years in sales management in the defense electronics industry with Alpha Industries, now Skyworks Solutions. He earned a Master of Business Administration degree from the Harvard Business School, a Bachelor of Science degree in Business Management from Bucknell University, and holds the Chartered Financial Analyst (CFA) designation. "Perlegen has assembled an unparalleled array of talent and technology that is swiftly moving pharmacogenomics from a promise to a reality," said Mr. Middlebrook. "Perlegen is intensely focused on accelerating, and bringing to a production scale, its technology to help physicians and patients in their quest for safe and effective medications. I am thrilled to help execute this mission." About Perlegen Sciences Perlegen conducts genetics research and develops products that impact and improve people's lives through a proprietary, cost-effective method for rapidly analyzing and comparing entire genomes. This whole genome association study capability enables Perlegen to identify genes that work in concert to cause common diseases and affect the body's response to drugs. Perlegen is applying its genotyping capabilities in ongoing pharmacogenomic and other research collaborations with partners including: Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Pfizer and Unilever. Formed in late 2000 as a spin-off of Affymetrix, Inc. (NASDAQ:AFFX), Perlegen is accelerating the development of therapeutics and diagnostics and enabling a new paradigm of high-resolution whole genome scanning. For more information about Perlegen and its technologies, visit Perlegen's web site at http://www.perlegen.com/. Perlegen, the Perlegen Logo and Perlegen Sciences are trademarks of Perlegen Sciences, Inc. Contact: Perlegen Sciences, Inc. Brad Margus Chief Executive Officer (650) 625-4500 DATASOURCE: Perlegen Sciences, Inc. CONTACT: Brad Margus Chief Executive Officer of Perlegen Sciences, Inc., +1-650-625-4500 Web site: http://www.perlegen.com/

Copyright